LAEKNA-B (02105) Rises Nearly 7% as FDA Accepts IND Application for New Drug LAE118

Stock News01-14

LAEKNA-B (02105) rose nearly 7% during the morning session. At the time of writing, the stock was up 5.88%, trading at HK$14.23 with a turnover of HK$9.34 million. On January 14, LAIKE Medicine announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118. LAE118 is a novel, pan-mutant selective PI3Kα inhibitor independently developed by Laike for the treatment of patients with solid tumors harboring PIK3CA mutations. PI3Kα mutations are relatively common in patients with breast cancer, colorectal cancer, lung cancer, endometrial cancer, and other cancers. Currently approved PI3Kα inhibitors globally lack selectivity for mutant types; they exhibit poor tolerability due to strong activity against the wild-type and are prone to developing resistance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment